Assembly Bill A1248B

2025-2026 Legislative Session

Prohibits the sale of xylazine above a certain weight

download bill text pdf

Sponsored By

Current Bill Status - In Senate Committee Consumer Protection Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

Bill Amendments

co-Sponsors

2025-A1248 - Details

See Senate Version of this Bill:
S7668
Current Committee:
Senate Consumer Protection
Law Section:
General Business Law
Laws Affected:
Add §392-k, Gen Bus L
Versions Introduced in 2023-2024 Legislative Session:
A6506, S6084

2025-A1248 - Summary

Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2025-A1248 - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   1248
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              January 9, 2025
                                ___________
 
 Introduced  by  M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, DE LOS SANTOS,
   SIMONE, FORREST, SHIMSKY,  LUCAS,  CUNNINGHAM,  CRUZ,  SIMON,  SAYEGH,
   EPSTEIN, BICHOTTE HERMELYN, BORES, K. BROWN, CHANG, GIGLIO, PIROZZOLO,
   DeSTEFANO  --  read  once  and  referred  to the Committee on Consumer
   Affairs and Protection

 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   §  392-K.  SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION, THE TERM
 "XYLAZINE" SHALL MEAN A PHARMACEUTICAL DRUG  USED  FOR  SEDATION,  ANES-
 THESIA,  MUSCLE  RELAXATION,  AND  ANALGESIA  IN ANIMALS SUCH AS HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2. NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,  FIRM,
 ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER XYLAZINE TO INDI-
 VIDUALS WITHOUT PROOF OF ITS INTENDED USE FOR INSTITUTIONAL, VETERINARY,
 OR SCIENTIFIC PURPOSES.
   3.  NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY, FIRM,
 ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN  THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER XYLAZINE TO INDI-
 VIDUALS UNDER THE AGE OF TWENTY-ONE.
   4.  ANY  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY COMPANY, FIRM,
 ONLINE PLATFORM OR OTHER BUSINESS  ENTITY  DOING  BUSINESS  WITHIN  THIS
 STATE  WHICH  KNOWINGLY SELLS, OFFERS FOR SALE, OR DISTRIBUTES XYLAZINE,
 SHALL REQUIRE AND RETAIN SALES RECORDS, PROOF OF AGE, AND PROOF  OF  USE
 FROM ALL PURCHASERS.
   5.  ANY  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY COMPANY, FIRM,
 ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN  THIS
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD02623-01-5

co-Sponsors

2025-A1248A - Details

See Senate Version of this Bill:
S7668
Current Committee:
Senate Consumer Protection
Law Section:
General Business Law
Laws Affected:
Add §392-k, Gen Bus L
Versions Introduced in 2023-2024 Legislative Session:
A6506, S6084

2025-A1248A - Summary

Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2025-A1248A - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  1248--A
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              January 9, 2025
                                ___________
 
 Introduced  by  M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, DE LOS SANTOS,
   SIMONE, FORREST, SHIMSKY,  LUCAS,  CUNNINGHAM,  CRUZ,  SIMON,  SAYEGH,
   EPSTEIN, BICHOTTE HERMELYN, BORES, K. BROWN, CHANG, GIGLIO, PIROZZOLO,
   DeSTEFANO,  PHEFFER AMATO,  WEPRIN  --  read  once and referred to the
   Committee on Consumer Affairs and Protection -- reported and  referred
   to the Committee on Codes -- reported and referred to the Committee on
   Ways   and  Means  --  committee  discharged,  bill  amended,  ordered
   reprinted as amended and recommitted to said committee
 
 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine above a certain weight
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   §  392-K.  SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION, THE TERM
 "XYLAZINE" SHALL MEAN A PHARMACEUTICAL DRUG  USED  FOR  SEDATION,  ANES-
 THESIA,  MUSCLE  RELAXATION,  AND  ANALGESIA  IN ANIMALS SUCH AS HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2. THE PROVISIONS OF THIS SECTION SHALL APPLY ONLY TO THE SALE,  OFFER
 FOR  SALE,  DELIVERY, OR DISTRIBUTION OF XYLAZINE IN QUANTITIES OF FIFTY
 GRAMS OR MORE.
   3. NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY,  FIRM,
 ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE  SHALL  KNOWINGLY  SELL, OFFER FOR SALE, OR DELIVER FIFTY GRAMS OR
 MORE OF XYLAZINE TO INDIVIDUALS WITHOUT PROOF OF ITS  INTENDED  USE  FOR
 INSTITUTIONAL, VETERINARY, OR SCIENTIFIC PURPOSES.
   4.  NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY, FIRM,
 ONLINE PLATFORM, OR OTHER BUSINESS ENTITY  DOING  BUSINESS  WITHIN  THIS
 STATE  SHALL  KNOWINGLY  SELL, OFFER FOR SALE, OR DELIVER FIFTY GRAMS OR
 MORE OF XYLAZINE TO INDIVIDUALS UNDER THE AGE OF TWENTY-ONE.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD02623-04-5
 A. 1248--A                          2

co-Sponsors

2025-A1248B (ACTIVE) - Details

See Senate Version of this Bill:
S7668
Current Committee:
Senate Consumer Protection
Law Section:
General Business Law
Laws Affected:
Add §392-k, Gen Bus L
Versions Introduced in 2023-2024 Legislative Session:
A6506, S6084

2025-A1248B (ACTIVE) - Summary

Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

2025-A1248B (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  1248--B
                                                            R. R. 202
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              January 9, 2025
                                ___________
 
 Introduced  by  M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, DE LOS SANTOS,
   SIMONE, FORREST, SHIMSKY,  LUCAS,  CUNNINGHAM,  CRUZ,  SIMON,  SAYEGH,
   EPSTEIN, BICHOTTE HERMELYN, BORES, K. BROWN, CHANG, GIGLIO, PIROZZOLO,
   DeSTEFANO, PHEFFER AMATO, WEPRIN, SANTABARBARA, WALSH -- read once and
   referred  to  the  Committee  on  Consumer  Affairs  and Protection --
   reported and referred to  the  Committee  on  Codes  --  reported  and
   referred  to  the Committee on Ways and Means -- committee discharged,
   bill amended, ordered reprinted as amended  and  recommitted  to  said
   committee  --  reported  and  referred  to  the  Committee on Rules --
   ordered to a third reading, passed by Assembly and  delivered  to  the
   Senate,  recalled  from  the  Senate, vote reconsidered, bill amended,
   ordered reprinted, retaining its place on the special order  of  third
   reading
 
 AN ACT to amend the general business law, in relation to prohibiting the
   sale of xylazine above a certain weight
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:

   Section 1. The general business law is amended by adding a new section
 392-k to read as follows:
   § 392-K. SALE OF XYLAZINE. 1. FOR PURPOSES OF THIS SECTION,  THE  TERM
 "XYLAZINE"  SHALL  MEAN  A  PHARMACEUTICAL DRUG USED FOR SEDATION, ANES-
 THESIA, MUSCLE RELAXATION, AND ANALGESIA  IN  ANIMALS  SUCH  AS  HORSES,
 CATTLE, AND OTHER NON-HUMAN MAMMALS.
   2.  THE PROVISIONS OF THIS SECTION SHALL APPLY ONLY TO THE SALE, OFFER
 FOR SALE, DELIVERY, OR DISTRIBUTION OF XYLAZINE IN QUANTITIES  OF  FIFTY
 GRAMS OR MORE PER OCCURRENCE.
   3.  NO  CORPORATION,  PARTNERSHIP,  LIMITED  LIABILITY  COMPANY, FIRM,
 ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS
 STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER  FIFTY  GRAMS  OR
 MORE  OF  XYLAZINE  TO INDIVIDUALS WITHOUT PROOF OF ITS INTENDED USE FOR
 INSTITUTIONAL, VETERINARY, OR SCIENTIFIC PURPOSES.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.